Han Jingyan, Shuvaev Vladimir V, Davies Peter F, Eckmann David M, Muro Silvia, Muzykantov Vladimir R
Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine of the Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA19104, USA; Vascular Biology Section, Department of Medicine, Boston University, Boston, MA 02421, USA.
Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine of the Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA19104, USA.
J Control Release. 2015 Jul 28;210:39-47. doi: 10.1016/j.jconrel.2015.05.006. Epub 2015 May 9.
Targeting nanocarriers (NC) to endothelial cell adhesion molecules including Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1 or CD31) improves drug delivery and pharmacotherapy of inflammation, oxidative stress, thrombosis and ischemia in animal models. Recent studies unveiled that hydrodynamic conditions modulate endothelial endocytosis of NC targeted to PECAM-1, but the specificity and mechanism of effects of flow remain unknown. Here we studied the effect of flow on endocytosis by human endothelial cells of NC targeted by monoclonal antibodies Ab62 and Ab37 to distinct epitopes on the distal extracellular domain of PECAM. Flow in the range of 1-8dyn/cm(2), typical for venous vasculature, stimulated the uptake of spherical Ab/NC (~180nm diameter) carrying ~50 vs 200 Ab62 and Ab37 per NC, respectively. Effect of flow was inhibited by disruption of cholesterol-rich plasmalemma domains and deletion of PECAM-1 cytosolic tail. Flow stimulated endocytosis of Ab62/NC and Ab37/NC via eliciting distinct signaling pathways mediated by RhoA/ROCK and Src Family Kinases, respectively. Therefore, flow stimulates endothelial endocytosis of Ab/NC in a PECAM-1 epitope specific manner. Using ligands of binding to distinct epitopes on the same target molecule may enable fine-tuning of intracellular delivery based on the hemodynamic conditions in the vascular area of interest.
将纳米载体(NC)靶向至包括血小板内皮细胞黏附分子-1(PECAM-1或CD31)在内的内皮细胞黏附分子,可改善动物模型中炎症、氧化应激、血栓形成和缺血的药物递送及药物治疗。最近的研究表明,流体动力学条件可调节靶向PECAM-1的NC的内皮细胞内吞作用,但血流影响的特异性和机制仍不清楚。在此,我们研究了血流对人内皮细胞内吞作用的影响,这些内皮细胞内吞的NC由单克隆抗体Ab62和Ab37靶向PECAM远端细胞外结构域上的不同表位。1-8dyn/cm²范围内的血流是静脉血管的典型情况,它刺激了球形Ab/NC(直径约180nm)的摄取,每个NC分别携带约50个与200个Ab62和Ab37。富含胆固醇的质膜结构域的破坏和PECAM-1胞质尾的缺失可抑制血流的作用。血流分别通过引发由RhoA/ROCK和Src家族激酶介导的不同信号通路,刺激Ab62/NC和Ab37/NC的内吞作用。因此,血流以PECAM-1表位特异性方式刺激Ab/NC的内皮细胞内吞作用。使用与同一靶分子上不同表位结合的配体,可能能够根据感兴趣血管区域的血流动力学条件对细胞内递送进行微调。